Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine
Open Access
- 1 April 2000
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 74 (7), 3020-3028
- https://doi.org/10.1128/jvi.74.7.3020-3028.2000
Abstract
We constructed chimeric dengue type 2/type 1 (DEN-2/DEN-1) viruses containing the nonstructural genes of DEN-2 16681 virus or its vaccine derivative, strain PDK-53, and the structural genes (encoding capsid protein, premembrane protein, and envelope glycoprotein) of DEN-1 16007 virus or its vaccine derivative, strain PDK-13. We previously reported that attenuation markers of DEN-2 PDK-53 virus were encoded by genetic loci located outside the structural gene region of the PDK-53 virus genome. Chimeric viruses containing the nonstructural genes of DEN-2 PDK-53 virus and the structural genes of the parental DEN-1 16007 virus retained the attenuation markers of small plaque size and temperature sensitivity in LLC-MK2cells, less efficient replication in C6/36 cells, and attenuation for mice. These chimeric viruses elicited higher mouse neutralizing antibody titers against DEN-1 virus than did the candidate DEN-1 PDK-13 vaccine virus or chimeric DEN-2/DEN-1 viruses containing the structural genes of the PDK-13 virus. Mutations in the envelope protein of DEN-1 PDK-13 virus affected in vitro phenotype and immunogenicity in mice. The current PDK-13 vaccine is the least efficient of the four Mahidol candidate DEN virus vaccines in human trials. The chimeric DEN-2/DEN-1 virus might be a potential DEN-1 virus vaccine candidate. This study indicated that the infectious clones derived from the candidate DEN-2 PDK-53 vaccine are promising attenuated vectors for development of chimeric flavivirus vaccines.Keywords
This publication has 37 references indexed in Scilit:
- Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate against Japanese EncephalitisVirology, 1999
- Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primatesVaccine, 1999
- Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteersVaccine, 1996
- The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolutionNature, 1995
- Dengue Virus-Specific Memory T Cell Responses in Human Volunteers Receiving a Live Attenuated Dengue Virus Type 2 Candidate VaccineThe Journal of Infectious Diseases, 1994
- Direct sequencing of large flavivirus PCR products for analysis of genome variation and molecular epidemiological investigationsJournal of Virological Methods, 1992
- FLAVIVIRUS GENOME ORGANIZATION, EXPRESSION, AND REPLICATIONAnnual Review of Microbiology, 1990
- Identification of Monoclonal Antibodies that Distinguish Between 17D-204 and other Strains of Yellow Fever VirusJournal of General Virology, 1990
- STUDY OF BIVALENT DENGUE VACCINE IN VOLUNTEERSThe Lancet, 1989
- Pathogenesis of Dengue: Challenges to Molecular BiologyScience, 1988